NCT04537767

The Effect of Esmolol on Patients With Sepsis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock and sepsis.

Detailed description

Severe sepsis, septic shock, and their complications have become the major healthcare problem that affects millions of people each year, resulting in high mortality rates. Septic responses have an extremely complex chain of events including inflammatory and anti-inflammatory processes, humoral and cellular reactions, and cardiocirculatory abnormalities. Esmolol may have some potential in treating septic shock and sepsis. The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock and sepsis.

Conditions

• Sepsis

Interventions

Type	Name	Description
DRUG	Esmolol	The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.
DRUG	Placebo	Placebo

Timeline

• Start date: 2020-10-01
• Primary completion: 2023-03-31
• Completion: 2023-09-30
• First posted: 2020-09-03
• Last updated: 2020-09-03